Sensory Function After Wound Instillation of Capsaicin

NCT ID: NCT00583180

Last Updated: 2008-01-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

42 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-01-31

Study Completion Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The use of capsaicin as a potential analgesic drug for postoperative pain relies on the ability of capsaicin to induce membrane lysis of c-nerve fibers. In a previous randomized placebo controled blinded study of this effect we found a significant effect of capsaicin versus placebo. Before surgery all patients were examined by quantitative sensory testing to evaluate sensory function. In this study an identical sensory testing will examine if changes to the sensory function in capsaicin treated patients is identical to placebo treated patients.No new intervention will be performed

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Hyperalgesia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Primary and/or secondary hyperalgesia hypoesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Capsaicin treated patients

Capsaicin

Intervention Type DRUG

instillation of sterile water or 1000 micrograms of capsaicin into the wound at the end of open groin hernia surgery in previous study.no new intervention will be performed in the current study.

P

Placebo treated patients

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Capsaicin

instillation of sterile water or 1000 micrograms of capsaicin into the wound at the end of open groin hernia surgery in previous study.no new intervention will be performed in the current study.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ALGRX 4975 ADLEA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary groin hernia planned to undergo Lichtenstein mesh repair
* Ability to use pain scales
* American Society of Anesthesiologist class I or II based upon medical history, physical examination, and screening laboratory results
* Willing to take oral pain medication (acetaminophen, ibuprofen) for the first week
* Willing to fill out a diary for four weeks following surgery.

Exclusion Criteria

* A previous lower abdominal surgical procedure
* Bupivacaine, acetaminophen, ibuprofen, or tramadol
* A medical condition likely to alter wound healing or pain ratings
* Systolic blood pressure greater than 150 or diastolic greater than 95 mm Hg
* Contraindication to general anesthesia
* Bilateral hernia repair
* A history of drug or alcohol abuse within the past two years
* Use of antihypertensive, antidepressant, or psychotropic drug that has not been stable for 3 months
* Use of an investigational drug within 3 months or scheduled to receive an investigational drug other than ALGRX 4975 during the study period.
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rigshospitalet, Denmark

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rigshospitalet

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Henrik Kehlet, M.D, Ph. D.

Role: STUDY_DIRECTOR

Rigshospitalet, Denmark

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hørshol Sygehus

Hørsholm, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4975-2008-01

Identifier Type: -

Identifier Source: org_study_id